Glans sheath devices
This article was originally published in The Gray Sheet
Executive Summary
FDA proposed rule scheduled for publication in the May 10 Federal Register proposes that a premarket approval application or a notice of completion of a product development protocol be required for marketing of the preamendments product (21 CFR 884.5320). Comments on the proposal are due in 90 days
You may also be interested in...
FDA In Brief
August ENT panel meeting: FDA's Ear Nose and Throat Devices Panel will meet Aug. 16 in Gaithersburg, Maryland to discuss and make recommendations on the recently issued implantable middle ear hearing device draft guidance (1"The Gray Sheet" June 17, 2002, p. 11). Topics to be addressed include "appropriate study population, objective measurement techniques for comparison of acoustic hearing aids and middle ear hearing devices and subjective questionnaire development for determining postoperative effectiveness and quality of life outcomes," according to the 2ENT meeting announcement. Requests for formal oral presentations should be submitted to FDA by Aug. 8...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”